Last reviewed · How we verify
NCT06631963
Telehealth Group-based Emotional Awareness and Expression Therapy for Patients With Persistent Physical Symptoms: A Pilot Study
NA trial testing Emotional Awareness and Expression Therapy in Somatic Symptom and Related Disorders in 50 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Daniel Maroti |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Emotional Awareness and Expression Therapy
Conditions studied
- Somatic Symptom and Related Disorders — all drugs for Somatic Symptom and Related Disorders →
- Somatic Symptom Disorder — all drugs for Somatic Symptom Disorder →
- Functional Somatic Disorder — all drugs for Functional Somatic Disorder →
- Functional Somatic Syndrome — all drugs for Functional Somatic Syndrome →
Sponsor
Daniel Maroti
Who can join
18 and older, any sex, with Somatic Symptom and Related Disorders or Somatic Symptom Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Delivering Emotional Awareness and Expression Therapy (EAET) through digital or telehealth platforms in a group format offers several key advantages. First, it significantly improves access to care, allowing individuals with persistent physical symptoms (PPS) to receive effective, emotion-focused therapy regardless of their geographic location. Telehealth can also benefit those who face mobility issues or have limited access to specialized care in rural or underserved areas. Group-based telehealth EAET promotes social connection among participants, fostering a supportive environment where individuals can share experiences, which may enhance therapeutic outcomes. Additionally, the convenience of remote therapy can reduce barriers to participation, such as time constraints and travel costs, making it easier for patients to commit to treatment. Finally, the digital format allows for flexible, scalable interventions that can be easily integrated into routine psychiatric care, potentially increasing treatment uptake for individuals who might otherwise avoid in-person therapy due to stigma or logistical challenges.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06631963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Emotional Awareness and Expression Therapy
Trials testing the same drug.
- NCT05989230 — Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma · NA · recruiting
- NCT06044649 — Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain · NA · recruiting
- NCT06004804 — Group-Based Psychological Treatments Over Video Conference for Older Veterans With Chronic Pain · NA · recruiting
- NCT05755698 — Emotional Awareness and Expression Therapy (EAET) for Migraine · NA · terminated
- NCT04552860 — vEAET for Older Veterans With Chronic Musculoskeletal Pain Pilot · NA · completed
Other Daniel Maroti trials
Trials by the same sponsor.
- NCT06682104 — ISTDP for Patients with Treatment Resistance PPS · NA · not yet recruiting
- NCT06631911 — Emotional Awareness and Expression Therapy for Patients With Persistent Physical Symptoms in Routine Psychiatric Care: A · NA · not yet recruiting
- NCT06301360 — Internet Based Emotional Awareness and Expression Therapy for Functional Somatic Disorder With and Without Therapist Sup · NA · unknown
- NCT06149182 — Does the First Interview Matter: A Comparing Life Stress Interview Versus a Standard Psychiatric Intake Interview for Pa · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06631963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daniel Maroti
- Last refreshed: 8 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06631963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing